Similarly, a separate study identified a patient with metastatic melanoma who demonstrated a partial response to the combination of anti-PD-1 and anti-CTLA-4 therapy but later developed treatment-resistant metastasis with acquired PTEN loss (69). Here, PDCD1 is linked to metastatic melanoma.